Insilico Medicine

AI-driven drug discovery

3696 · HKEX · China / United States

Public Market Listing

3696HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Insilico Medicine are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
PHD1/2Small molecule
Inflammatory Bowel Disease
Ulcerative Colitis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
August 2027 (1)
garutadustatPhase 2Ulcerative Colitis
Est. primary completion 2027-08-15 · NCT07265570 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

3 June 2025Topline resultRentosertibPhase IIa GENESIS-IPF results published in Nature Medicine

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$27M$36M$213M$9.6Mreport ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$56M$81M$393M$88Mreport ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$86M$92M$126M$4.3Mreport ↗
2023-FY$51M$97M$177M$53Mreport ↗
2022-FY$30M$78M$208M$55Mreport ↗